Overview: Viral Pulmonary Screen Panel TestIntroduction: The Viral Pulmonary Screen Panel Test screens for viral respiratory pathogens to diagnose infections, causing cough. Aligned with 2023 IDSA guidelines, it uses molecular or antigen-based methods for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in clinical diagnostics for patients with suspected respiratory infections. Note: Test Parameters are not specified in input data; typically includes detection of multiple viral pathogens.
Other Names: Viral Respiratory Panel, Pulmonary Viral Screen.
FDA Status: Laboratory-developed test (LDT), meeting clinical diagnostic standards for accuracy.
Historical Milestone: Viral respiratory panels began in the 2000s with multiplex PCR research. Molecular methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Screens for viral respiratory pathogens to diagnose infections, guides treatment, and evaluates patients with cough.
Test Parameters: Not specified in input data; typically includes influenza, RSV, and other respiratory viruses.
Pretest Condition: No fasting required. Collect nasopharyngeal swab, bronchoalveolar lavage, or sputum. Report history of cough or respiratory symptoms.
Specimen: Nasopharyngeal Swab (sterile swab/transport medium, 1-2 swabs), Bronchoalveolar Lavage (sterile container, 5-10 mL), Sputum (sterile container, 5-10 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: Not specified in input data; typically 2 hours.
Sample Stability at Refrigeration: Not specified in input data; typically 24 hours.
Sample Stability at Frozen: Not specified in input data; typically not frozen.
Medical History: Document cough, fever, or history of respiratory infections. Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, respiratory infection implications, and risks of sample collection.
Procedural Considerations: Uses multiplex PCR or antigen testing to detect respiratory viral pathogens. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for respiratory infection diagnosis.
Factors Affecting Result Accuracy: Improper sample collection or contamination can affect results. Low viral load may reduce sensitivity.
Clinical Significance: Positive viral detection confirms respiratory infection, guiding antiviral or supportive therapy. Negative results may require bacterial culture or imaging.
Specialist Consultation: Consult an infectious disease specialist or pulmonologist for result interpretation and treatment planning.
Additional Supporting Tests: Bacterial culture, chest imaging, or specific viral PCR to confirm respiratory infection diagnosis.
Test Limitations: Limited to detectable viruses; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Respiratory Infection Guidelines, 2023; Clinical Infectious Diseases, Hanson KE, 2022.
